Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. Tobira’s management team has extensive experience in developing and commercializing therapeutics for liver disease and HIV-1. The lead indication for CVC is non-alcoholic steatohepatitis, or NASH, for which Tobira plans to begin a Phase 2 clinical trial in the second half of 2014. The company believes there are no other product candidates in development for NASH that target the immuno-inflammatory pathways responsible for fibrosis. CVC also is Phase 3-ready in HIV-1 infection with potential as the backbone in a fixed-dose combination therapy. CVC is a once-daily pill with a safety and tolerability profile that has been established to date in 550 subjects dosed in completed Phase 1 and Phase 2 trials, including 115 HIV-1 infected subjects on treatment for up to 48 weeks.